MX2020001628A - Cristales de base libre de (6ar, 9as)-5,6a,7,8,9,9a-hexahidro-5-me til-3-(fenilamino-2-((4-((6-fluoropiridin-2-il)fenil)metil)-ciclo pent[4,5]imidazo[1,2-a]pirazolo[4,3-e]pirimidin-4(2h)-ona. - Google Patents

Cristales de base libre de (6ar, 9as)-5,6a,7,8,9,9a-hexahidro-5-me til-3-(fenilamino-2-((4-((6-fluoropiridin-2-il)fenil)metil)-ciclo pent[4,5]imidazo[1,2-a]pirazolo[4,3-e]pirimidin-4(2h)-ona.

Info

Publication number
MX2020001628A
MX2020001628A MX2020001628A MX2020001628A MX2020001628A MX 2020001628 A MX2020001628 A MX 2020001628A MX 2020001628 A MX2020001628 A MX 2020001628A MX 2020001628 A MX2020001628 A MX 2020001628A MX 2020001628 A MX2020001628 A MX 2020001628A
Authority
MX
Mexico
Prior art keywords
free base
crystals
base crystals
methyl
cyclopent
Prior art date
Application number
MX2020001628A
Other languages
English (en)
Inventor
Lawrence P Wennogle
Peng Li
Robert Davis
Graham Buckton
Mark Hooper
Takashi Abe
Hideaki Maruyama
Masahiro Takasuga
Yuhei Yamamoto
Hironori Yamashita
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of MX2020001628A publication Critical patent/MX2020001628A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a cristales de (6aR,9aS)-5,6a,7,8,9,9a-hexahidro-5-metil-3-(fenilamino)-2-((4-(6 -fluoropiridin-2-il)fenil)metil)-ciclopent[4,5]imidazo[1,2-a]pira zolo[4,3-e]pirimidin-4(2H)-ona, y métodos para hacer y usar tales cristales.
MX2020001628A 2013-06-21 2015-12-21 Cristales de base libre de (6ar, 9as)-5,6a,7,8,9,9a-hexahidro-5-me til-3-(fenilamino-2-((4-((6-fluoropiridin-2-il)fenil)metil)-ciclo pent[4,5]imidazo[1,2-a]pirazolo[4,3-e]pirimidin-4(2h)-ona. MX2020001628A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361838105P 2013-06-21 2013-06-21
US201361919424P 2013-12-20 2013-12-20

Publications (1)

Publication Number Publication Date
MX2020001628A true MX2020001628A (es) 2020-07-13

Family

ID=52105535

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015017972A MX2015017972A (es) 2013-06-21 2014-06-20 Cristales de base libre.
MX2020001628A MX2020001628A (es) 2013-06-21 2015-12-21 Cristales de base libre de (6ar, 9as)-5,6a,7,8,9,9a-hexahidro-5-me til-3-(fenilamino-2-((4-((6-fluoropiridin-2-il)fenil)metil)-ciclo pent[4,5]imidazo[1,2-a]pirazolo[4,3-e]pirimidin-4(2h)-ona.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015017972A MX2015017972A (es) 2013-06-21 2014-06-20 Cristales de base libre.

Country Status (14)

Country Link
US (1) US9630971B2 (es)
EP (2) EP3010509B1 (es)
JP (2) JP6865036B2 (es)
KR (2) KR20160040522A (es)
CN (3) CN105658222A (es)
AU (1) AU2014284224B2 (es)
BR (1) BR112015032132B1 (es)
CA (1) CA2916393C (es)
ES (1) ES2894770T3 (es)
HK (1) HK1223848A1 (es)
IL (2) IL243269B (es)
MX (2) MX2015017972A (es)
RU (1) RU2675851C2 (es)
WO (1) WO2014205354A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6051210B2 (ja) 2011-06-10 2016-12-27 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
AR091507A1 (es) 2012-06-21 2015-02-11 Intra Cellular Therapies Inc SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
AU2014284224B2 (en) 2013-06-21 2019-08-01 Intra-Cellular Therapies, Inc. Free base crystals
WO2021226407A1 (en) * 2020-05-06 2021-11-11 Intra-Cellular Therapies, Inc. Free base crystals
WO2023034965A2 (en) * 2021-09-03 2023-03-09 Intra-Cellular Therapies, Inc. Co-crystals
WO2023147484A1 (en) * 2022-01-27 2023-08-03 Intra-Cellular Therapies, Inc. Novel compositions
WO2023233410A1 (en) * 2022-06-02 2023-12-07 Biosight Ltd. Crystalline form of aspacytarabine intermediate

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9412571D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
US5471001A (en) * 1994-12-15 1995-11-28 E. I. Du Pont De Nemours And Company Crystallization of adipic acid
GB9624615D0 (en) 1996-11-26 1997-01-15 Zeneca Ltd Chrystallisation process
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
CA2475498C (en) 2002-02-08 2011-05-10 Ono Pharmaceutical Co., Ltd. Piperidine derivative and pharmaceutical composition comprising the same as active ingredient
WO2004087906A1 (en) 2003-03-31 2004-10-14 Pfizer Products Inc. Crystal structure of 3',5'-cyclic nucleotide phosphodiesterase 1b (pde1b) and uses thereof
EP1662876A4 (en) * 2003-09-02 2009-01-14 Merck & Co Inc NOVEL CRYSTALLINE FORMS OF A PHOSPHORIC ACID SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
KR101260036B1 (ko) * 2004-09-27 2013-05-06 아카디아 파마슈티칼스 인코포레이티드 Ｎ－(４－플루오로벤질)－ｎ－(１－메틸피페리딘－４－일)－ｎ＇－(４－(２－메틸프로필옥시)페닐메틸)카르바미드와그의 타르트레이트염 및 결정형의 합성
BRPI0611095B8 (pt) 2005-06-06 2021-05-25 Intracellular Therapies Inc compostos inibidores de pde1, composição farmacêutica compreendendo-os, usos dos mesmos como inibidores de pde1 para o tratamento de doenças relacionadas, tal como doença de parkinson e deficiência cognitiva, e métodos para produção dos ditos compostos
US9198924B2 (en) 2006-11-13 2015-12-01 Intra-Cellular Therapies, Inc. Organic compounds
WO2008070095A1 (en) 2006-12-05 2008-06-12 Intra-Cellular Therapies, Inc. Novel uses
ES2436780T3 (es) * 2007-12-06 2014-01-07 Takeda Pharmaceutical Company Limited Compuestos orgánicos
EP2370080A1 (en) 2008-12-02 2011-10-05 University of Utah Research Foundation Pde1 as a target therapeutic in heart disease
CN102231953A (zh) 2008-12-06 2011-11-02 细胞内治疗公司 有机化合物
EP2358204B1 (en) 2008-12-06 2015-08-05 Intra-Cellular Therapies, Inc. 4,5,7,8-tetrahydro-4-oxo-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine compounds as PDE1 inhibitors.
EP2358723B1 (en) 2008-12-06 2015-05-13 Intra-Cellular Therapies, Inc. 4,5,7,8-tetrahydro-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine compounds as PDE1 inhibitors
WO2010098839A1 (en) 2009-02-25 2010-09-02 Intra-Cellular Therapies, Inc. Pde 1 inhibitors for ophthalmic disorders
EP2434895A4 (en) * 2009-05-13 2013-08-07 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
WO2011043816A1 (en) 2009-10-08 2011-04-14 Intra-Cellular Therapies, Inc. Phosphodiesterase 1-targeting tracers and methods
JP5911854B2 (ja) 2010-05-31 2016-04-27 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
JP6051210B2 (ja) 2011-06-10 2016-12-27 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
AR091507A1 (es) 2012-06-21 2015-02-11 Intra Cellular Therapies Inc SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
AU2014284224B2 (en) 2013-06-21 2019-08-01 Intra-Cellular Therapies, Inc. Free base crystals

Also Published As

Publication number Publication date
EP3010509B1 (en) 2021-07-28
WO2014205354A2 (en) 2014-12-24
US20160145261A1 (en) 2016-05-26
EP3010509A4 (en) 2016-11-23
KR102430126B1 (ko) 2022-08-05
KR20210122890A (ko) 2021-10-12
CN105658222A (zh) 2016-06-08
MX2015017972A (es) 2016-10-28
BR112015032132A2 (pt) 2017-07-25
CN112851683A (zh) 2021-05-28
US9630971B2 (en) 2017-04-25
JP2016523258A (ja) 2016-08-08
AU2014284224B2 (en) 2019-08-01
EP3010509A2 (en) 2016-04-27
WO2014205354A3 (en) 2015-05-28
BR112015032132B1 (pt) 2022-03-15
IL243269B (en) 2019-06-30
IL243269A0 (en) 2016-02-29
AU2014284224A1 (en) 2016-02-11
HK1223848A1 (zh) 2017-08-11
IL267331A (en) 2019-08-29
JP6865036B2 (ja) 2021-04-28
EP3702358A1 (en) 2020-09-02
ES2894770T3 (es) 2022-02-15
RU2016101630A3 (es) 2018-03-21
CN110498800A (zh) 2019-11-26
RU2016101630A (ru) 2017-07-26
JP2019189618A (ja) 2019-10-31
RU2675851C2 (ru) 2018-12-25
KR20160040522A (ko) 2016-04-14
CA2916393A1 (en) 2014-12-24
CA2916393C (en) 2022-03-22

Similar Documents

Publication Publication Date Title
MX2020001628A (es) Cristales de base libre de (6ar, 9as)-5,6a,7,8,9,9a-hexahidro-5-me til-3-(fenilamino-2-((4-((6-fluoropiridin-2-il)fenil)metil)-ciclo pent[4,5]imidazo[1,2-a]pirazolo[4,3-e]pirimidin-4(2h)-ona.
HRP20190152T1 (hr) Kombinacija pirolo[2,3-d]pirimidinskih derivata s jednim ili više dodatnih sredstava kao inhibitori kinaza srodnih janus kinazi (jak)
MX352831B (es) Cristales de sal.
IL229606A0 (en) Pyrazolone [3, 4-d] pyrimidine compounds and their use as 2pde inhibitors and/or 4a3 cyp inhibitors
PH12013501402A1 (en) Mesoionic Pyrido [1,2 -A] Pyrimidine Pesticides
AU2011288503A8 (en) 6-Cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as PDE9A inhibitors
IL243092B (en) New triazolo[d–4,5]pyrimidine histories
IL227526A0 (en) Derivatives of 6-cyclobutyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidine-4-one and their use as a9pde inhibitors
IL288674A (en) 7-Benzyl-4-(2-methylbenzyl)-2, 4, 6, 7, 8, 9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidine-5(1h)one, its salts and methods Use
ZA201403441B (en) [1,2,3]triazolo[4,5-d]pyrimidine derivatives as agonists of the cannabinoid
HRP20182021T1 (hr) Derivati [1,2,4]triazolo[1,5-a]pirimidina kao inhibitori proteazoma protozoe za liječenje parazitskih bolesti poput lišmenijaze
EP2523552A4 (en) PYRAZOLO- [1,5-A] PYRIMIDINE AS MARK HEMMER
UA79045U (en) 2-amino-4,7-dimethyl-8-phenylcarbamoyl-9-(2-chlorophenyl)-3-cyanopyrido[2',3' : 4,5]thieno[2,3-b]pyridine
UA78668U (en) 2-AMINO-4,8,8-TRIMETHYL-10-OXO-11-(4-CHLOROPHENYL)-3-CYANO-6,7,8,9,10,11-HEXAHYDROPYRIDO[2',3' : 4,5]THIENO[2,3-b]QUINOLINE
UA86579U (en) 2-AMINO-4-METHYL-9-(1-NAPHTHYL)-7-OXO-3-CYANO-6,7,8,9-TETRAHYDROPYRIDO[3',2':4,5]THIENO[3,2-b]PYRIDINE
UA85086U (en) 2-amino-4-methyl-7-oxo-9-(2-chlorophenyl)-3-cyano-6,7,8,9-tetrahydropyrido[3',2':4,5]thieno[3,2-b]pyridine
UA63370U (en) Use of 4,3'-spiro[(2-amino-3-cyano-4,5-dihydropyrano[3,2-c]chromen-5-on)-5-methyl-2'-oxyndole] as nephroprotective agent